Licaminlimab for Dry Eye Syndrome (RELIEF Trial)

Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Oculis

Prior Safety Data

Trial Summary

What is the purpose of this trial?The goal of this clinical trial is to learn about licaminlimab (OCS-02) in the treatment of dry eye disease. The main question it aims to answer is if licaminlimab ophthalmic suspension is more effective than vehicle in treating signs of dry eye disease.

Eligibility Criteria

This trial is for adults over 18 with dry eye disease lasting at least 6 months, who regularly use artificial tears and have certain scores on eye tests (Schirmer's Test, corneal staining, conjunctival redness). Participants must see well enough (20/100 vision or better) and agree to follow the study rules.

Inclusion Criteria

I have had dry eye disease in both eyes for at least 6 months.

I have moderate to severe eye surface damage confirmed by tests.

I am 18 years old or older.

I have reported moderate to severe dry eye symptoms.

Treatment Details

The trial is testing licaminlimab ophthalmic suspension against a placebo (vehicle of OCS-02) to see if it's more effective in treating signs of dry eye disease. It will compare improvements between the two treatments.

2Treatment groups

Experimental Treatment

Placebo Group

Group I: licaminlimab (OCS-02)Experimental Treatment1 Intervention

60 mg/mL licaminlimab ophthalmic suspension

Group II: VehiclePlacebo Group1 Intervention

Vehicle of licaminlimab (OCS-02) ophthalmic suspension